Physician profile
Ashleigh E Ames
NPI 1922674456
$11,002.47
in general payments reported to CMS, 2019-2025
39 companies · $1,991 in 2025
The $1,991 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $927 · 2022: $2,503 · 2023: $2,780 · 2024: $2,802 · 2025: $1,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,518 · Travel and Lodging: $33.75 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,517.53 |
| Travel and Lodging | $33.75 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,397.99 | 2021-2025 | Relistor |
| Abbvie INC. | $1,295.27 | 2021-2025 | |
| Boston Scientific Corporation | $1,216.82 | 2021-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Collegium Pharmaceutical, INC. | $1,207.46 | 2021-2025 | Belbuca, Xtampza |
| Protega Pharmaceutials INC | $681.55 | 2022-2025 | Roxybond |
| Lundbeck LLC | $535.04 | 2021-2025 | Vyepti |
| Ibsa Pharma INC. | $447.42 | 2021-2025 | Tirosint, Licart, Tirosint |
| Biohaven Pharmaceutical Holding Company LTD. | $417.18 | 2022 | |
| Amgen INC. | $407.49 | 2022-2025 | Evenity, Prolia |
| Medtronic, INC. | $399.45 | 2021-2024 | Synchromedii, Intellis Adaptivestim |
| Nevro Corp. | $336.17 | 2022-2024 | Senza |
| Globus Medical, INC. | $333.37 | 2025 | Senza |
| Saluda Medical Americas, INC. | $288.16 | 2023-2025 | Evoke, Evoke Scs |
| Biohaven Pharmaceuticals, INC. | $271.76 | 2021 | |
| Pfizer INC. | $212.97 | 2023-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $210.97 | 2023-2025 | Qutenza |
| Abbott Laboratories | $200.42 | 2023 | Octrode, Eterna, Proclaim |
| Grt US Holding, INC. | $183.73 | 2021-2022 | |
| Tersera Therapeutics LLC | $179.75 | 2021-2025 | Prialt |
| Azurity Pharmaceuticals, INC. | $112.02 | 2023-2024 | Horizant, Horizant |
| Curonix LLC | $70.65 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ipsen Biopharmaceuticals, INC | $66.25 | 2023-2024 | Dysport |
| Allergan, INC. | $59.97 | 2021-2022 | |
| Lilly USA, LLC | $57.40 | 2022-2023 | Emgality |
| Csl Behring | $47.86 | 2022-2023 | Hizentra |
| Merz Pharmaceuticals, LLC | $42.18 | 2022-2025 | Xeomin |
| Redhill Biopharma INC. | $41.14 | 2022 | |
| Spr Therapeutics, INC | $39.13 | 2022 | |
| Virtus Pharmaceuticals LLC | $29.34 | 2021 | |
| Almatica Pharma LLC | $28.27 | 2021 | |
| Vertos Medical, INC. | $26.48 | 2024 | Mild Device Kit |
| Radius Health, INC. | $25.56 | 2022 | |
| Biotronik Nro, INC. | $21.79 | 2025 | Prospera |
| Kowa Pharmaceuticals America, INC. | $21.18 | 2023 | Seglentis |
| Hikma Pharmaceuticals USA | $21.00 | 2024 | Kloxxado |
| Depuy Synthes Sales INC. | $20.82 | 2024 | Orthovisc, Peak |
| Arbor Pharmaceuticals, INC. | $17.88 | 2022 | |
| Pacira Therapeutics, INC. | $16.69 | 2021 | |
| Biodelivery Sciences International, INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashleigh Ames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.